Considering the immunocytochemical results, all melanoma cell lines (7/7; 100%) with concurrent mutation of BRAF-NRAS and down-regulation of p16CDKN2A presented high expression levels of the activated pERK1-2 protein (Figure 1). The gene discussed is NRAS; the disease is melanoma.